OC Fair announces new CEO as July opening nears

About a month before the return of the Orange County Fair, the event's board of directors announced Monday it has found a new chief executive officer.
James Canfield will succeed Michele Richards, who announced in January she would retire in May to move to Georgia and help care for family members.
His first day on the job will be July 1. The annual fair returns July 18 and runs through Aug. 17.
Canfield most recently served as senior director and general manager of the Birmingham Jefferson Convention Complex in Alabama.
The position at the OC Fair & Event Center in Costa Mesa marks a return to California, where he previously held management roles at convention centers in Palm Springs, Pasadena and Long Beach.
'I am very excited to return to California and to have the great opportunity to lead OC Fair & Event Center into a new era that builds on its rich legacy while advancing innovation and community-focused programming,' Canfield said in a news release issued Monday by the OC Fair & Event Center Board of Directors. 'I am very much looking forward to opening day of this year's OC Fair.'
OC Board Chairman Nick Kovacevich praised Canfield's 'extensive experience in managing premier convention and entertainment venues,' calling him 'exceptionally well-suited to lead our organization into its nextchapter.''
Kovacevich added that Canfield's 'innovative approach and dedication to operational excellence will ensure that the OC Fair and our year-round events continue to be cherished community traditions delivering joy, education and memorable experiences to all who visit. We look forward to the fresh perspective and dynamic leadership he will bring to our team.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hypebeast

an hour ago

• Hypebeast

Kering Hires New CEO & Francesco Risso Exits Marni in This Week's Top Fashion News

RenaultCEO Luca de Meo will take the helm atKering, following the announcement of Kering Chairman and CEO François-Henri Pinault's departure. Pinault had been leading the conglomerate, which ownsGucci,Bottega Veneta,Balenciaga,Dior, and more, for 20 years since 2005. The appointment brings optimism to Kering, where significant struggles have taken hold, particularly with its once-dominant brand, Gucci, experiencing steep declines in sales and profitability. The current chief executive of Renault will step down from his current role in mid-July, and he'll take over the luxury conglomerate on September 15. Meanwhile, Kering's current CEO, François-Henri Pinault, will maintain his role as Chairman of the Board of Directors. In a statement, de Meo said, 'I would like to thank François-Henri Pinault and the Board of Directors for choosing me to lead Kering into this new phase of development. I am approaching this new professional challenge with enthusiasm, eagerness, and confidence, inspired by the strength of the Group's brands and the expertise of its people. I am convinced that together we will continue to make Kering an essential player in the luxury industry.' After a decade,Francesco Rissohas stepped down as Creative Director ofMarni. Appointed in 2016, Risso significantly expanded upon founder Consuelo Castiglioni's legacy, bringing a craft-geared ethos and vibrant aesthetic to a new generation of luxury consumers. His distinctive chunky knitwear, bohemian florals, and collaborations with artists likeErykah Baduresonated strongly with Gen Z and Millennials. Risso's departure is part of a series of changes at parent company OTB Group, which owns brands like Diesel and Jil Sander. While Marni has not yet named a successor, speculation points to a potential return to a female perspective, with names likeMartine Rosebeing considered for her offbeat, colorful vision that aligns with Marni's distinct identity. Nikehas officially resolved its trademark dispute withThe Shoe Surgeon, settling the lawsuit initiated in 2024. The agreement includes an undisclosed payment from The Shoe Surgeon to Nike. Under the terms, The Shoe Surgeon is barred from using any Nike branding that might confuse consumers. However, he can continue creating unique custom sneakers, but only under conditions approved by Nike. In a statement to Sneaker Bar Detroit, the Shoe Surgeon expressed his aspiration to collaborate with 'legendary brands'. He also conveyed confusion regarding Nike's decision to pursue litigation over discussion, while expressing confidence that a resolution can be achieved through dialogue with Nike's new management. He emphasized that 'creating defines us' and that 'authenticity is stitched into our DNA,' concluding with 'Where there is unity, there is victory'. Children of the Discordancereturned toPitti Uomo108, showcasing an expressive collection of reworked garments inspired by defiant youth cultures and urban chaos. Designer Hideaki Shikama likened his design approach to DJing, focusing on remixed and 'chopped-and-screwed' sensibilities. The collection features fine tailoring in structured pieces like skirts and jackets, balanced with edgy elements such as patinated over-dye and deconstructed silhouettes. Patchwork suiting blends tonal fabrics, while dark fabric scraps are quilted into textiles for various garments. The 'discordance' concept is evident in halved garments sewn down the middle, including a Japanese souvenir jacket and a graphic football jersey. The presentation concluded with an unconventional bridal look made from crumpled t-shirts, adorned with a bejeweled cross on a hood-veil hybrid. Revealed at its FW25/26 presentation last January,Louis Vuittonhas launched the release of its highly-anticipated LV BUTTERSOFT sneaker, unveiling a versatile lineup of 24 colorways — including monogrammed pairs. Paying homage to the style of the 2000s hip-hop community,Pharrell's latest footwear design combines the luxury craftsmanship of a dress shoe with the comfortable silhouette of a retro sneaker. The special campaign spotlights the shoe's key design details, including an LV logo on the lateral panel and an embossed 'Phriendship silhouette' of Pharrell's face at the tongue. Furthermore, on the back of the shoe, an embossed lobster is an Easter egg detail calling back to Pharrell and Nigo's collaborative relationship. Crafted by Italian artisans with ultra-soft leather, the 'buttery' material gives the shoe a pillow-like quality. The elevated platform soles depart from the flat-soled footwear trends offered by luxury competitors like Miu Miu and Loewe. With a silhouette verging on appearing cartoon-like, the design echoes the Minecraft-esque pixelated motifs featured in Pharrell's earlier collections for the Maison. Telfaris celebrating its 20th anniversary with a unique 'New Models' series, airing as an hour-long special on June 18 at 8 p.m. ET. This innovative broadcast will feature contestants vying for a spot on Telfar's upcoming New York City runway show. Viewers can actively participate by voting live to select the winners. Described as a blend of game show and media experiment, the series will be available on TELFARTV, Telfar's self-owned public access platform. It challenges conventional modeling standards, aiming to redefine representation within the fashion industry by questioning who typically gets visibility.

Business Wire

6 hours ago

• Business Wire

InvenTrust Properties Corp. Declares Second Quarter 2025 Cash Dividend

DOWNERS GROVE, III.--(BUSINESS WIRE)--InvenTrust Properties Corp. (NYSE: IVT) announced today that its Board of Directors declared a second quarter 2025 cash distribution of $0.2377 per share of common stock, which represents a 5% year-over-year increase. When annualized, this is equal to a rate of $0.9508 per share. This distribution will be paid on or about July 15, 2025, to stockholders of record as of June 30, 2025. About InvenTrust Properties Corp. InvenTrust Properties Corp. is a premier Sun Belt, multi-tenant essential retail REIT that owns, leases, redevelops, acquires and manages grocery-anchored neighborhood and community centers as well as high-quality power centers that often have a grocery component. Management pursues the Company's business strategy by acquiring retail properties in Sun Belt markets, opportunistically disposing of retail properties, maintaining a flexible capital structure, and enhancing environmental, social and governance practices and standards.

Yahoo

8 hours ago

• Yahoo

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market RulesNantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a 'Questions and Answers' document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with market rules. In line with its continuous information and transparency approach towards shareholders, the Company has published a "Questions and Answers" document, accessible at the following address: intended to answer the main questions of shareholders regarding recent events. Nicolas Poirier, CEO of OSE, states: "We have a responsibility to all those who expect seriousness and results from OSE, primarily the patients. We cannot leave the false information communicated to the market unanswered. For example, there is no plan to use venture debt instruments. In response to these unfounded rumors, we have decided to publish this "Questions and Answers" document. An exchange with all shareholders will be organized soon in the same spirit." Following the declaration of a concerted action and the submission of several resolutions aimed at significantly altering the composition of the Board of Directors by a group of shareholders1, the Company reminds the market, that it had requested and obtained, by order of the President of the Nantes Commercial Court dated June 10, 2025, the postponement of the General Meeting initially scheduled for June 25, 20252. The "group of shareholders" notified the Company today of their challenge to this decision, through a request for the retraction of the June 10, 2025 order, with a hearing scheduled for Tuesday, June 24, 2025. The postponement of the General Meeting to a later date, aims to address the concerns expressed by certain shareholders in this tense context and to ensure that the consultation of its shareholders can take place in a serene democratic framework, ensuring complete and fair information. This general meeting cannot be a stage for attempts to destabilize and spread erroneous information about the Company. In this regard, OSE Immunotherapeutics has filed a request today with the Nantes Commercial Court, within the framework of an accelerated procedure (known as "fixed date"), for an action against this same group of shareholders. This action concerns the regularity of the declaration of the concerted action, with the aim of ensuring compliance with the principles of transparency governing shareholder democracy ahead of the Company's next General Meeting. Subject to the evolution of legal proceedings, the Company currently plans to hold the General Meeting on September 30, 2025. In this context, the Board of Directors reaffirms its commitment in favor of a transparent, responsible and constructive dialogue among all stakeholders. This commitment is reflected in the procedures and actions undertaken by the Company but also by the joint mobilization of the management and the Board of Directors to install a dialogue with the "group of shareholders". A constructive and formal framework for exchange has thus been proposed to move forward together in the interest of the Company and all its shareholders. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 Press release of June 9, 20252 Press release of June 11, 2025 Attachment EN_250620_FINALSign in to access your portfolio